Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

P43235 (CATK_HUMAN) Homo sapiens (Human)

Cathepsin K UniProtKBInterProSTRINGInteractive Modelling

329 aa; Sequence (Fasta)

Available Structures

69 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Structure of Pycnonodysostosis disease related I249T mutant of human cathepsin Khomo-2-mer16-329
GOL; 16×EDO;SO4;PEG;CL;NA;MPD;
Assess
CRYSTAL STRUCTURE OF WILD TYPE HUMAN PROCATHEPSIN Khomo-2-mer16-329
Assess
Structure of the activation intermediate of cathepsin K in complex with the 3-cyano-3-aza-beta-amin…homo-2-mer23-329
A0U;ACT;MG;
Assess
Structure of the activation intermediate of cathepsin K in complex with the azadipeptide nitrile in…homo-2-mer23-329
9ZG;EDO;CL;MG;
Assess
The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Ca…homo-2-mer115-329
HVW;CA;CL;
Assess
Cathepsin K complexed with a ketoamide inhibitorhomo-2-mer115-329
SO4;FSP;
Assess
Crystal structure of the cathepsin K : chondroitin sulfate complex.homo-2-mer115-329
BDP;CA;E64;
Assess
THE CRYSTAL STRUCTURE OF HUMAN PROCATHEPSIN Kmonomer20-329
Assess
Human cathepsin K mutant C25S in complex with the allosteric effector NSC13345monomer107-329
1XF;SO4;
Assess
Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914monomer108-329
6HM;SO4;
Assess
Structure of cathepsin K in complex with the azadipeptide nitrile inhibitor Gu1303monomer113-329
9ZG;CL;ACT;
Assess
Cathepsin-K in complex with MIV-711monomer113-329
J5N;NO3;
Assess
Cathepsin-K in complex with MIV-701monomer114-329
HFH;GOL;NA;
Assess
Structure of human cathepsin K in complex with the selective activity-based probe Gu3416monomer114-329
SO4;UUW;
Assess
Structure of human cathepsin K in complex with the acrylamide inhibitor Gu3110monomer114-329
SO4;UUK;
Assess
Cathepsin-K in complex with amino-oxaazabicyclo[3.3.0]octanyl containing inhibitormonomer114-329
MHA;J6B;
Assess
Crystal structure of a pyrrolopyrimidine inhibitor in complex with human Cathepsin Kmonomer114-329
CKE;
Assess
Cathepsin-K in complex with MIV-710monomer114-329
J5T;CL;NA;
Assess
Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor…monomer114-329
IHJ;
Assess
Cathepsin-K in complex with fluoro-oxa-azabicyclo[3.3.0]octanyl containing inhibitormonomer114-329
HKH;
Assess
Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor…monomer114-329
IHI;
Assess
Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inh…monomer115-329
3XT;I37;SO4;
Assess
Crystal structure of Cathepsin K with a covalently-linked inhibitor at 1.4 Angstrom resolution.monomer115-329
7AS;
Assess
Crystal structure of human Cathepsin K with a non-active site inhibitor at 1.42 Angstrom resolutionmonomer115-329
1XF;
Assess
Cathepsin K in complex with a non-selective 2-cyano-pyrimidine inhibitormonomer115-329
SO4;KWZ;
Assess
Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inh…monomer115-329
GOL;CL;K;PGO;3Y2;
Assess
Crystal structure of uninhibited human Cathepsin K at 1.62 Angstrom resolutionmonomer115-329
Assess
Cathepsin K inhibitormonomer115-329
0LC;SO4;
Assess
Cathepsin K covalently bound to a 2-cyano pyrimidine inhibitor with a benzyl P3 group.monomer115-329
SO4;O75;
Assess
Cathepsin K inhibitormonomer115-329
0LB;GOL;
Assess
Cathepsin K covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over hERGmonomer115-329
O47;
Assess
X-ray structure of Cathepsin K covalently bound to a triazine ligandmonomer115-329
ORG;TFA;
Assess
Crystal structure of Cathepsin K complexed with a potent vinyl sulfone inhibitormonomer115-329
0D6;
Assess
Structure of human Cathepsin K with an ectosteric inhibitor at 1.85 Angstrom resolutionmonomer115-329
J0V;
Assess
Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inh…monomer115-329
3Y1;SO4;
Assess
Structure of cathepsin K in complex with the 3-cyano-3-aza-beta-amino acid inhibitor Gu2602monomer115-329
A0U;
Assess
Cathepsin K complexed with a pyrrolidine ketoamide-based inhibitormonomer115-329
4PR;
Assess
Crystal structure of a potent small molecule inhibitor bound to cathepsin Kmonomer115-329
NFT;
Assess
Crystal structure of Human Cathepsin K in complex with myocrisinmonomer115-329
SO4;MYQ;
Assess
Sulfonated Calpeptin is a promising drug candidate against SARS-CoV-2 infectionsmonomer115-329
CA;
Assess
Structure of CatK covalently bound to a dioxo-triazine inhibitormonomer115-329
ORH;
Assess
Cathepsin K complexed with t-butyl(1S)-1-cyclohexyl-2-oxoethylcarbamatemonomer115-329
SO4;TCO;
Assess
CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT SYMMETRIC BISCA…monomer115-329
INA;
Assess
CRYSTAL STRUCTURE OF CATHEPSIN K WITH N-DESMETHYL THALASSOSPIRAMIDE Cmonomer115-329
G4B;
Assess
CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH THE COVALENT INHIBITOR…monomer115-329
E64;
Assess
Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor…monomer115-329
IHE;
Assess
The crystal structure of the cathepsin K Variant M5 in complex with chondroitin-4-sulfatemonomer115-329
BDP;CA;E64;
Assess
CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT THIAZOLHYDRAZID…monomer115-329
IN6;
Assess
Cathepsin K complexed with a semicarbazone inhibitormonomer115-329
SO4;CT2;
Assess
CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PEPTIDOMIMETIC …monomer115-329
I10;
Assess
CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PYRROLIDINO…monomer115-329
INP;
Assess
CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT BENZYLOXYBENZOY…monomer115-329
IN3;
Assess
CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT AZEPANONE I…monomer115-329
2CA;
Assess
CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PYRROLIDINO…monomer115-329
PCM;
Assess
Cathepsin K complexed with a cyanopyrrolidine inhibitormonomer115-329
NBL;
Assess
CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT SYMMETRIC D…monomer115-329
SDK;
Assess
CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PROPANONE I…monomer115-329
POS;
Assess
Structure of Cathepsin K-dermatan sulfate complexmonomer115-329
ASG;
Assess
Crystal Structure Of The Cysteine Protease Human Cathepsin K In Complex With A Covalent Azepanone I…monomer115-329
750;
Assess
Human cathepsin K mutant C25Smonomer116-329
SO4;ACT;CL;
Assess
Cathepsin K complexed with a constrained ketoamide inhibitormonomer116-329
SO4;3FC;
Assess
Cathepsin K complexed with carbamate derivatized norleucine aldehydemonomer116-329
SO4;MYE;
Assess
Cathepsin K in complex with a selective 2-cyano-pyrimidine inhibitormonomer117-329
KX1;SO4;
Assess
Cathepsin K co-crystallized with actinomycetes extractmonomer117-329
SO4;
Assess
Crystal structure of cathepsin K bound to the covalent inhibitor lichostatinalmonomer117-329
SO4;
Assess
cathepsin K - chondroitin sulfate complexmonomer117-329
BDP;
Assess
Cathepsin K complexed with a semicarbazone inhibitormonomer117-329
CT1;
Assess
Cathepsin K complexed with a cyanamide-based inhibitormonomer117-329
T2M;
Assess
Cathepsin K in complex with a covalent inhibitor with a ketoamide warheadmonomer121-329
O96;SO4;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5z5o.1.Amonomer0.8916-329
99.36
Assess